Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 9/20 | 0.39 |
| ▸ | EP300 | Q09472 | 6/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751688 | 0.88 | EPHX2 (0.44) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL25734929 | 0.87 | GGPS1 (0.40) | EPHX2HRH4HRH3DGAT1NR1H4 | |
| SCHEMBL26382134 | 0.84 | EPHX2 (0.48) | EPHX2GBA1EP300 | |
| SCHEMBL25446424 | 0.83 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL22695703 | 0.83 | EPHX2 (0.43) | EPHX2GBA1EP300HRH4HRH3 | |
| SCHEMBL25735002 | 0.83 | EPHX2 (0.47) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL23974562 | 0.82 | EPHX2 (0.43) | EPHX2GBA1EP300HRH4HRH3 | |
| SCHEMBL24974617 | 0.82 | EP300 (0.43) | EPHX2GBA1EP300DGAT1 | |
| SCHEMBL25734931 | 0.81 | HRH4 (0.49) | HRH4HRH3NR1H4 | |
| SCHEMBL25446423 | 0.80 | DGAT1 (0.51) | EPHX2EP300DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |